Federal Agency Ends Funding for Asthma Study, Citing Unnecessary Health Improvements
The Agency for Healthcare Research and Quality has declared that funding for Dr. Lisa DeCamp's innovative asthma study must be terminated immediately, citing the alarming prospect that the program could actually lead to healthier children and reduced Medicaid costs. Officials stated that while it might seem counterintuitive, a successful program could inadvertently lead to budgetary constraints if fewer children require treatment.
In a baffling twist of bureaucratic logic, agency spokespersons have proposed a new policy whereby successful health initiatives will be evaluated on their potential to increase the number of patients requiring services, thereby ensuring a steady flow of funding. This bold strategy stems from a belief that health improvements should be closely monitored to prevent any unforeseen budget surpluses.
Still Beats Watergate:
Sponsor success. Continue reading:
The agency's decision has sparked outrage among public health advocates who argue that improving health outcomes should take precedence over maintaining bureaucratic budgets. However, in a demonstration of administrative certainty, the agency has introduced a new metric known as the "Health Improvement Risk Factor" (HIRF), which quantifies the likelihood that a successful health project could lead to a decrease in patient numbers. The higher the HIRF score, the more likely the project will face funding cuts.
Agency's Bold New Funding Philosophy
A spokesperson for the agency confidently proclaimed that this new metric would revolutionize the way health initiatives are funded, stating, "We believe in giving money only to those programs that can maintain the status quo of illness. By prioritizing our funding in this manner, we are safeguarding against the terrifying prospect of healthier Americans."
Your takeaway
As the dust settles from this latest funding debacle, Dr. DeCamp and her colleagues are left pondering how to navigate an increasingly hostile landscape where success is, quite literally, a path to funding extinction. In an ironic twist, some researchers are now considering deliberately underestimating the efficacy of their programs to ensure ongoing financial support.
This new funding philosophy is set to take effect immediately, with the agency urging all researchers to submit their proposals for projects that promise minimal health improvements or, preferably, decline in patient wellness. If the agency's plans succeed, it could usher in a new era of healthcare where mediocrity reigns supreme, and innovation is relegated to the fringes of federal support.





